Public Health Service Act (PHSA), outlined in 42 U.S.C. 262(k) and later detailed in numerous FDA guidance documents.

Key points regarding the interchangeability designation include:

• The transition between products must not lead to significant differences in safety or efficacy.
• The sponsor must demonstrate that the biosimilar can be expected to produce the same clinical result as the reference product in any given patient.
• For certain biological products, the FDA may require switching studies to validate interchangeability.

Documentation

To obtain an interchangeability designation, the applicant must provide extensive documentation supporting the application. This includes:

1. Quality Data

The CMC section must detail information about manufacturing, characterization, and quality control. Applicants must use a consistent process for both the biosimilar and reference product, presenting solid arguments for product similarity.

2. Nonclinical Study Data

Comprehensive nonclinical studies assessing pharmacodynamics, pharmacokinetics, and immunogenicity profiles are essential. The data should demonstrate comparable safety margins and immunogenicity between the biosimilar and referenced product.

3. Clinical Study Data

This is the most critical section for interchangeability. Depending on the product, clinical studies must include:

• Clinical efficacy and safety trials comparing the biosimilar and the reference product.
• Switching studies that assess whether patients can safely switch from the reference product to the biosimilar.

4. Switching Studies

A switching study is required to demonstrate that a patient can safely alternate between the reference product and the biosimilar without compromising therapeutic effectiveness or increasing safety risks. The design of these studies typically involves:

• A head-to-head comparison of the biosimilar and reference product.
• Assessment of pharmacokinetic parameters, efficacy endpoints, and safety outcomes.

Review/Approval Flow

The review process for a biosimilar interchangeability designation follows a structured flow, which includes the following steps:

1. Pre-IND Submission: Interactions with the FDA to discuss study designs and regulatory requirements.
2. IND Submission: Filing an Investigational New Drug application, followed by clinical study initiation.
3. BLA Submission: Once pivotal studies are completed, submitting a Biologics License Application (BLA) that includes requests for interchangeability.
4. FDA Review: The FDA will examine the submission, leading to potential requests for additional information or revisions.
5. Approval and Labeling: Upon approval, the labeling must reflect the interchangeability status, including indications for switching.

Common Deficiencies

During the review of interchangeability designations, the FDA has identified several common deficiencies that sponsors should be wary of, including:

• Insufficient Clinical Data: Failure to adequately demonstrate equivalent safety and efficacy outcomes can lead to rejection. Trials should comprehensively address different patient populations and potential impact from switching.
• Weak Justification for Bridging Data: If reliance on existing data is claimed, sponsors must provide robust scientific justification for its applicability to the US market.
• Poor handling of Immunogenicity Data: Incomplete investigations into immunogenic response can cause significant issues, particularly in establishing trust in the interchangeability claims.

RA-Specific Decision Points

Certain decision points are crucial for regulatory professionals working on biosimilar interchangeability designations:

When to File as Variation vs. New Application

Determining whether to file a variation or a new application is pivotal and generally depends upon:

• The extent of changes to the formulation or manufacturing process that affects the quality and efficacy of the biosimilar.
• The necessity for new data supporting the change, especially in the case of a new indication or show of interchangeability.

Justifying Bridging Data

When presenting bridging data, it is essential to:

• Provide a clear rationale of the relevance and applicability of the data from other populations or indications.
• Highlight any mechanistic similarities between the original data and the context of the proposed biosimilar use.

Conclusion

Achieving biosimilar interchangeability designation in the United States requires thorough preparation, from understanding legal frameworks to executing robust clinical studies that tackle switching. Regulatory professionals must stay updated on FDA guidelines and expectations, employing careful consideration of submission strategies and documentation of evidence supporting interchangeable biosimilars. By adhering to regulatory requirements and preparing diligently, organizations can successfully navigate the intricacies of biosimilar interchangeability designation.

For more detailed regulatory guidelines, refer to the FDA’s guidance document on biosimilars.